We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Arthro Kinetics | AKI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.10 | 0.10 |
| Top Posts |
|---|
Posted at 13/6/2007 13:51 by hopestaruk Arthro Kinetics European PatentRNS Number:2927Y Arthro Kinetics plc 13 June 2007 Press Release Arthro Kinetics plc - granted European patent WEDNESDAY, 13th June 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro Kinetics"), the orthopedics company dedicated to regenerating joint mobility and spinal disc function, announces that its wholly owned subsidiary Arthro Kinetics AG has been granted a European patent (EP 1 289 574) for "Cartilage Replacement and Methods for the Production Thereof". Jason Loveridge, CEO of Arthro Kinetics commented: "This is excellent news for Arthro Kinetics and validation of the novelty of our R&D and product portfolio for cartilage regeneration. This patent extends coverage for our core proprietary technology - from which our first product CaReS(R) emerged onto the market in 2003 - to an additional 19 European countries beyond Germany, where the original application was filed in May 2001. We are continuing to pursue protection across all key commercial markets and, in this respect, the European patent represents an important piece of intellectual property protecting our core technology and portfolio of products for cartilage regeneration". END Contact Jason Loveridge Tel: +49 (0)711 305 110 70 Chief Executive, Arthro Kinetics plc |
Posted at 04/6/2007 11:27 by katylied Always a good sign when Huge arrives looking for value.But caution Huge. AKI spend alot on trying to shift their product. I doubt £6m is still left... |
Posted at 27/2/2007 19:00 by katylied So... What is it all about?... My take on the state of play...At present AKI has 50m authorised shares of 20p nominal value. There are ~28m shares (fully paid) in issue. The current MktCap at today's mid of 14p, is therefore ~£4m. The company is still loss-making. There is ~£1.9m cash on the balance-sheet, but also a similar amount of debt. The EGM called for 22/03/2007 is to authorise a capital-reorganisati So... subject to that EGM, AKI will be reorganised to have 200m (4:1) authorised new shares of 5p nomial value. The 27,600,481 old (20p) shares already in issue will be re-nominalised (1:1) at 5p (the additional new 15p shares are simply a device to achieve that end. They will always be worthless and can be ignored). There will be a subscription of ~44m new (5p) shares at 10p/share and a placing of 16m new (5p) shares at 10p/share. This will raise ~£6m gross and increase the total shares in issue to ~88m. There will also be warrants for future issue of an additional ~30m shares at 20p/share and options for a further ~10% of the enlarged share issue, at prices from 15p to 50p. At today's 14p mid-price, the post EGM MktCap would be ~£12m with net balance-sheet cash of ~£6m... The new funds will cover a further 12 months, but beyond that company trading will have to improve substantially. The size of future losses will be key. If the cash just burns away, then a ~£12m MktCap looks much too high. In that event, the share-price could halve, rather sooner than it might double... |
Posted at 27/2/2007 10:50 by learntlesson Hey Katy, _ haven't looked at AKI for a while - but from my understanding they took a hit in November when the Germans told them they needed an authorisation to by the tissue cultures, and then on 30th of Jan this year they got that authorisation. I think in light of the possible value, some of that dilution may already have been accounted for. This could see a nice reversal? |
Posted at 30/11/2006 09:39 by katylied Rather long RNS out today... lots of waffle, but the important bit comes right at the end ...the Board believes that the Company will require additional capital. The Company expects to initiate a fund raising in January 2007...Dilution is likely to be extreme. So AKI must surely now be a no go area this side of Feb 2007... |
Posted at 27/11/2006 19:05 by jonwig Hi, adgd2,Tianjin Anda will own 85% of the JV, AKI 15%. My reading is that the Chinese have paid 10 million (cash) to the JV for the stake, AKI have provided the IP. |
Posted at 26/9/2006 07:30 by jonwig This could address some capex fears, though giving away some profits further ahead:TUESDAY, 26th September 2006 - Arthro Kinetics plc (AIM: AKI) ('Arthro Kinetics' or 'the Company'), the pioneer orthopaedics company dedicated to regenerating joint mobility and spinal disc function, announces that it has signed a memorandum of understanding for the establishment of a joint venture with Tianjin Anda Group Holding Co. Ltd ('Tianjin Anda') for the commercialisation in China of its CaReS biologic cartilage regeneration products. |
Posted at 29/8/2006 10:18 by kamitora It's easy to suggest the original placing was overpriced in the light of the 50% fall recently, but for five months this traded near that price, so the market seemed to consider it fairly valued until that mysterious 150k sell caused chaos.I agree there are a lot of regulatory hurdles to overcome and probably because I used to work in the industry (in orthopaedics including spinal) I'm not keen on investing in early stage medical companies - they are notoriously difficult to value. That said, the valuation for AKI and companies like it is pocket change to the company I used to work for and they buy them all the time - I think usually the moment they think the target company has some potentially integrate-able technology (that they don't want their competitors to have!) If AKI is successful with its products I'd be very surprised if they made it to profitability before being snapped up, so this is always going to be valued speculatively rather on fundamentals. Still, they do have a revenue stream which is more than a lot of companies in their position. I haven't got around to looking at the company's main area of research in-depth but I know it's in a very desireable area. As for the surgical instruments produced for minimally invasive surgery, this should certainly be a substantially growing market because minimally invasive is very much the way forward for operative procedures for probably obvious reasons. The only problem with surgical instruments in general (and minimally invasive instruments are no different) is an ongoing debate about the risks of patient-to-patient contamination as there is some evidence to suggest that modern methods of sterilising instruments are not 100% effective. There is a risk that governments will eventually mandate disposable instruments instead of re-usable ones which I don't believe AKI produce at the moment. In any case, this is only a secondary area of their business. |
Posted at 23/8/2006 11:27 by jonwig Edited transcript of the interview on WallStreetReporter:WSR: Give us a brief overview of the company. AKI: We started as Ars Arthro in 1999, focusing on biological, cellular, and acellular regeneration. We grew quickly, bringing the first products into human clinical trial use in October of 2002. In the beginning of 2004, we started marketing a product called CaReS, an autologous cellular matrix product for focal cartilage defects of the knee. Following that, we joined forces with Endospine Kinetics, an innovative start-up company in the U.K., which focused on minimally-invasive access systems and new techniques for spinal surgery. The vision behind that was to combine innovative, regenerative technologies with minimally-invasive access systems. With that background, we took the first step with the public listing and then positioned ourselves to bring these technologies not only together but also to internationalize the operations, which have been focused in the German-speaking market. WSR: Give us some insight into the overall size of the market and some of the drivers behind this space. AKI: These were previously traditional markets in other words, where symptoms were addressed by either symptomatic pain management therapy or joint replacement products. It's been only ten years since the first biological product has been used in the knee joint it's a new and developing market. With the technology we have, we are confident we can make joint resurfacing a realistic option and an additional treatment alternative for the orthopedic surgeon, which will open up at least 50% of the existing knee replacement market, or U.S.$3 billion to U.S.$4 billion worldwide. WSR: Talk about the company's products, services, and technologies, as well as available market applications. AKI: On the knee side, we would be talking about a real total option -- various cartilage replacement products besides the first product we have on the market. There will be acellular products coming out in the European market by the end of this year and a further complete resurfacing product is planned here in Europe for the beginning of 2007. On top of that, there is a meniscus project in development, which should go into human trials by the end of next year, as well as a ligament project. We believe these are required to meet the vision we have; when we go to the spinal side, we can now use that access system to put in biological nucleus regeneration, which will be a cascade of four to five different products, depending on the degree of disc degeneration -- human trials are only two years away. WSR: What is unique about Arthro Kinetics that sets it apart from its competitors? AKI: There has often been a misconception of regenerative technologies, particularly as they have existed up until now, not being economically viable. We believe we have addressed that issue with this matrix technology. This matrix is the core technology -- we can use that to embed cells or modify the matrix itself for the various indications and usages we are addressing. With that same advantage on the cellular side, it makes the process only ten days at the present time -- we can cut it down to a week. In addition, having the matrix as a core technology allows us internationally to decentralize the seeding part of the process, to use supply and license agreements and joint venture partners to go after the large emerging markets. WSR: Tell us how the company is competing at present in terms of present technologies and products. AKI: The most important trend is always commercial trend; the fact that there have always been significant biological products, which have now become really blockbuster products, especially on the BMP side, that has been a successful product, despite the long years and significant investments involved in those kinds of projects. That will pave the way for other biological and cellular products and other regenerative medicine products to be as successful as their predecessors. The second major trend is also a change in the mindset of the surgeons, because we are developing technologies that make the application of these products, especially in the cellular area, easier for the surgeon to apply, with very short operative times, often on an outpatient basis. WSR: How is the company positioned to capitalize on those trends? AKI: Having this matrix technology which makes specialty cellular therapy an implant that can be shaped and sized easily intraoperatively; it can be adapted to meet the different indications and applications required such as cartilage, meniscus, and ligaments, as well as disc degeneration. It's the first time that broad an application has been available in this form. WSR: What are some of the recent highlights and milestones the company has achieved? AKI: During the first quarter this year, we were very concerned about our resources being overstretched. The results were the opposite. Our company grew 100% over 2005. After that IPO, within the last two or three months, we've been able to recognize significant milestones in signing agreements to generate revenues over the next two or three years in various parts of the business, including distribution agreements in the patient markets in Europe, on top of that getting regulatory processes and the first approvals for a part of the product range in the U.S. WSR: Give us some insight into the key goals and strategies necessary for the company to ensure success. AKI: Getting experienced senior people into the various geographic locations in Asia, U.S. and Europe was very successfully started; we need to put additional resources in place in the next few months. We need to generate significant revenue growth and realize the potential we have in front of us with the technology at our disposal. WSR: When we talk about the company and its market valuation on the AIM, are there any peers we should look to in understanding and reconciling market valuation? AKI: When we look at some of the analyst reports, obviously, the peer group evaluation that they use, mainly in the orthopedic space, classical orthopedic companies, but also in the biologics and biomaterials area, those we believe would be companies that would be comparable. WSR: Give us some insight into any underlying strategies for existing partners or future alliances. AKI: On the R&D side, we look to keep good alliances, particularly on the university level, to see new development technologies coming ahead that might augment what we are doing, and have in terms of our technology portfolio and add to that wherever possible. In addition, on the distribution side, strategic alliances can be important in the major markets, to get excellent market coverage and quick growth into the market with the innovative technologies we are offering. That can lead to further opportunities in terms of M&A options which can come out of those specific alliances on the distribution and marketing side. WSR: In conclusion, what are the most compelling reasons one would invest in Arthro Kinetics? AKI: We can offer a real transformational technology, providing a whole new option of care in-between conservative pain management and joint replacement, both which will still have a place going forward, but in-between that, a regenerative option that can be administered in a minimally-invasive fashion. This would be provide a significant option to the therapies that are out there. We are putting the infrastructure and the people in place that are experienced and have a track record to show we can realize these growth potentials with this combination of technologies. |
Posted at 22/8/2006 09:21 by kamitora Hello LearntLesson - I'm interested in AKI as a short-term technical play. By comparison SOLA was a fundamentals play and I'm in it until the story changes - I think the big money there is to be made over the longer term.There was a distressed seller in AKI yesterday, we don't know why but last night I trawled through the prospectus (the pre-IPO lock-ins run up to next February), ran various news searches, checked the FDA website for any product /company warnings (a handy tip for medical companies), and came up blank. I think there may be a technical bounce though you have to wonder whether that seller has any more stock to unload. CODE probably picked up that 150K of stock and they don't look like they're moving until they've got rid of more of it. Will we run out of buyers before they run out of stock? I used to work in AKI's sector and looked over the company when it floated - though ultimately I passed on it. I like some of the company's technology. I think it may be attractive to potential predators, though probably not until more trials are done. But it's loss making - and will be for the foreseable future. It probably has enough cash for up to two years (barring exceptionals) but doubtless they'll be back to the market for more. Valuing companies like this is difficult. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
